Estimates of pandemic influenza vaccine effectiveness in Europe, 2009-2010: results of Influenza Monitoring Vaccine Effectiveness in Europe (I-MOVE) multicentre case-control study

Background: A multicentre case-control study based on sentinel practitioner surveillance networks from seven European countries was undertaken to estimate the effectiveness of 2009-2010 pandemic and seasonal influenza vaccines against medically attended influenza-like illness (ILI) laboratory-confir...

Descripción completa

Detalles Bibliográficos
Autores: Valenciano, Marta, Kissling, Esther, Cohen, Jean-Marie, Oroszi, Beatrix, Barret, Anne-Sophie, Rizzo, Caterina, Nunes, Baltazar, Pitigoi, Daniela, Larrauri, Amparo, Mosnier, Anne, Horváth, Judit Krisztina, O'Donnell, Joan, Bella, Antonino, Guiomar, Raquel, Lupulescu, Emilia, Savulescu, Camelia, Ciancio, Bruno C, Kramarz, Piotr, Moren, Alain
Tipo de recurso: artículo
Fecha de publicación:2011
País:España
Institución:Instituto de Salud Carlos III (ISCIII)
Repositorio:Repisalud
Idioma:inglés
OAI Identifier:oai:repisalud.isciii.es:20.500.12105/6793
Acceso en línea:http://hdl.handle.net/20.500.12105/6793
Access Level:acceso abierto
Palabra clave:Adult
Aged
Case-Control Studies
Child
Child, Preschool
Europe
Female
Humans
Infant
Influenza, Human
Logistic Models
Male
Middle Aged
Odds Ratio
id ES_633debdf057a14ffc19c856d9a281dbd
oai_identifier_str oai:repisalud.isciii.es:20.500.12105/6793
network_acronym_str ES
network_name_str España
repository_id_str
spelling Estimates of pandemic influenza vaccine effectiveness in Europe, 2009-2010: results of Influenza Monitoring Vaccine Effectiveness in Europe (I-MOVE) multicentre case-control studyValenciano, MartaKissling, EstherCohen, Jean-MarieOroszi, BeatrixBarret, Anne-SophieRizzo, CaterinaNunes, BaltazarPitigoi, DanielaLarrauri, AmparoMosnier, AnneHorváth, Judit KrisztinaO'Donnell, JoanBella, AntoninoGuiomar, RaquelLupulescu, EmiliaSavulescu, CameliaCiancio, Bruno CKramarz, PiotrMoren, AlainAdultAgedCase-Control StudiesChildChild, PreschoolEuropeFemaleHumansInfantInfluenza, HumanLogistic ModelsMaleMiddle AgedOdds RatioBackground: A multicentre case-control study based on sentinel practitioner surveillance networks from seven European countries was undertaken to estimate the effectiveness of 2009-2010 pandemic and seasonal influenza vaccines against medically attended influenza-like illness (ILI) laboratory-confirmed as pandemic influenza A (H1N1) (pH1N1). Methods and findings: Sentinel practitioners swabbed ILI patients using systematic sampling. We included in the study patients meeting the European ILI case definition with onset of symptoms >14 days after the start of national pandemic vaccination campaigns. We compared pH1N1 cases to influenza laboratory-negative controls. A valid vaccination corresponded to >14 days between receiving a dose of vaccine and symptom onset. We estimated pooled vaccine effectiveness (VE) as 1 minus the odds ratio with the study site as a fixed effect. Using logistic regression, we adjusted VE for potential confounding factors (age group, sex, month of onset, chronic diseases and related hospitalizations, smoking history, seasonal influenza vaccinations, practitioner visits in previous year). We conducted a complete case analysis excluding individuals with missing values and a multiple multivariate imputation to estimate missing values. The multivariate imputation (n = 2902) adjusted pandemic VE (PIVE) estimates were 71.9% (95% confidence interval [CI] 45.6-85.5) overall; 78.4% (95% CI 54.4-89.8) in patients <65 years; and 72.9% (95% CI 39.8-87.8) in individuals without chronic disease. The complete case (n = 1,502) adjusted PIVE were 66.0% (95% CI 23.9-84.8), 71.3% (95% CI 29.1-88.4), and 70.2% (95% CI 19.4-89.0), respectively. The adjusted PIVE was 66.0% (95% CI -69.9 to 93.2) if vaccinated 8-14 days before ILI onset. The adjusted 2009-2010 seasonal influenza VE was 9.9% (95% CI -65.2 to 50.9). Conclusions: Our results suggest good protection of the pandemic monovalent vaccine against medically attended pH1N1 and no effect of the 2009-2010 seasonal influenza vaccine. However, the late availability of the pandemic vaccine and subsequent limited coverage with this vaccine hampered our ability to study vaccine benefits during the outbreak period. Future studies should include estimation of the effectiveness of the new trivalent vaccine in the upcoming 2010-2011 season, when vaccination will occur before the influenza season starts.Public Library of Science (PLOS)Unión Europea. European Centre for Disease Prevention and Control (ECDC)20182018-12-1020112011-01-1120112011-01-11research articlehttp://purl.org/coar/resource_type/c_2df8fbb1VoRhttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/20.500.12105/6793reponame:Repisaludinstname:Instituto de Salud Carlos III (ISCIII)Inglésengopen accesshttp://purl.org/coar/access_right/c_abf2Atribución 4.0 Internacionalhttp://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:repisalud.isciii.es:20.500.12105/67932026-06-12T12:43:37Z
dc.title.none.fl_str_mv Estimates of pandemic influenza vaccine effectiveness in Europe, 2009-2010: results of Influenza Monitoring Vaccine Effectiveness in Europe (I-MOVE) multicentre case-control study
title Estimates of pandemic influenza vaccine effectiveness in Europe, 2009-2010: results of Influenza Monitoring Vaccine Effectiveness in Europe (I-MOVE) multicentre case-control study
spellingShingle Estimates of pandemic influenza vaccine effectiveness in Europe, 2009-2010: results of Influenza Monitoring Vaccine Effectiveness in Europe (I-MOVE) multicentre case-control study
Valenciano, Marta
Adult
Aged
Case-Control Studies
Child
Child, Preschool
Europe
Female
Humans
Infant
Influenza, Human
Logistic Models
Male
Middle Aged
Odds Ratio
title_short Estimates of pandemic influenza vaccine effectiveness in Europe, 2009-2010: results of Influenza Monitoring Vaccine Effectiveness in Europe (I-MOVE) multicentre case-control study
title_full Estimates of pandemic influenza vaccine effectiveness in Europe, 2009-2010: results of Influenza Monitoring Vaccine Effectiveness in Europe (I-MOVE) multicentre case-control study
title_fullStr Estimates of pandemic influenza vaccine effectiveness in Europe, 2009-2010: results of Influenza Monitoring Vaccine Effectiveness in Europe (I-MOVE) multicentre case-control study
title_full_unstemmed Estimates of pandemic influenza vaccine effectiveness in Europe, 2009-2010: results of Influenza Monitoring Vaccine Effectiveness in Europe (I-MOVE) multicentre case-control study
title_sort Estimates of pandemic influenza vaccine effectiveness in Europe, 2009-2010: results of Influenza Monitoring Vaccine Effectiveness in Europe (I-MOVE) multicentre case-control study
dc.creator.none.fl_str_mv Valenciano, Marta
Kissling, Esther
Cohen, Jean-Marie
Oroszi, Beatrix
Barret, Anne-Sophie
Rizzo, Caterina
Nunes, Baltazar
Pitigoi, Daniela
Larrauri, Amparo
Mosnier, Anne
Horváth, Judit Krisztina
O'Donnell, Joan
Bella, Antonino
Guiomar, Raquel
Lupulescu, Emilia
Savulescu, Camelia
Ciancio, Bruno C
Kramarz, Piotr
Moren, Alain
author Valenciano, Marta
author_facet Valenciano, Marta
Kissling, Esther
Cohen, Jean-Marie
Oroszi, Beatrix
Barret, Anne-Sophie
Rizzo, Caterina
Nunes, Baltazar
Pitigoi, Daniela
Larrauri, Amparo
Mosnier, Anne
Horváth, Judit Krisztina
O'Donnell, Joan
Bella, Antonino
Guiomar, Raquel
Lupulescu, Emilia
Savulescu, Camelia
Ciancio, Bruno C
Kramarz, Piotr
Moren, Alain
author_role author
author2 Kissling, Esther
Cohen, Jean-Marie
Oroszi, Beatrix
Barret, Anne-Sophie
Rizzo, Caterina
Nunes, Baltazar
Pitigoi, Daniela
Larrauri, Amparo
Mosnier, Anne
Horváth, Judit Krisztina
O'Donnell, Joan
Bella, Antonino
Guiomar, Raquel
Lupulescu, Emilia
Savulescu, Camelia
Ciancio, Bruno C
Kramarz, Piotr
Moren, Alain
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Unión Europea. European Centre for Disease Prevention and Control (ECDC)
dc.subject.none.fl_str_mv Adult
Aged
Case-Control Studies
Child
Child, Preschool
Europe
Female
Humans
Infant
Influenza, Human
Logistic Models
Male
Middle Aged
Odds Ratio
topic Adult
Aged
Case-Control Studies
Child
Child, Preschool
Europe
Female
Humans
Infant
Influenza, Human
Logistic Models
Male
Middle Aged
Odds Ratio
description Background: A multicentre case-control study based on sentinel practitioner surveillance networks from seven European countries was undertaken to estimate the effectiveness of 2009-2010 pandemic and seasonal influenza vaccines against medically attended influenza-like illness (ILI) laboratory-confirmed as pandemic influenza A (H1N1) (pH1N1). Methods and findings: Sentinel practitioners swabbed ILI patients using systematic sampling. We included in the study patients meeting the European ILI case definition with onset of symptoms >14 days after the start of national pandemic vaccination campaigns. We compared pH1N1 cases to influenza laboratory-negative controls. A valid vaccination corresponded to >14 days between receiving a dose of vaccine and symptom onset. We estimated pooled vaccine effectiveness (VE) as 1 minus the odds ratio with the study site as a fixed effect. Using logistic regression, we adjusted VE for potential confounding factors (age group, sex, month of onset, chronic diseases and related hospitalizations, smoking history, seasonal influenza vaccinations, practitioner visits in previous year). We conducted a complete case analysis excluding individuals with missing values and a multiple multivariate imputation to estimate missing values. The multivariate imputation (n = 2902) adjusted pandemic VE (PIVE) estimates were 71.9% (95% confidence interval [CI] 45.6-85.5) overall; 78.4% (95% CI 54.4-89.8) in patients <65 years; and 72.9% (95% CI 39.8-87.8) in individuals without chronic disease. The complete case (n = 1,502) adjusted PIVE were 66.0% (95% CI 23.9-84.8), 71.3% (95% CI 29.1-88.4), and 70.2% (95% CI 19.4-89.0), respectively. The adjusted PIVE was 66.0% (95% CI -69.9 to 93.2) if vaccinated 8-14 days before ILI onset. The adjusted 2009-2010 seasonal influenza VE was 9.9% (95% CI -65.2 to 50.9). Conclusions: Our results suggest good protection of the pandemic monovalent vaccine against medically attended pH1N1 and no effect of the 2009-2010 seasonal influenza vaccine. However, the late availability of the pandemic vaccine and subsequent limited coverage with this vaccine hampered our ability to study vaccine benefits during the outbreak period. Future studies should include estimation of the effectiveness of the new trivalent vaccine in the upcoming 2010-2011 season, when vaccination will occur before the influenza season starts.
publishDate 2011
dc.date.none.fl_str_mv 2011
2011-01-11
2011
2011-01-11
2018
2018-12-10
dc.type.none.fl_str_mv research article
http://purl.org/coar/resource_type/c_2df8fbb1
VoR
http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.openaire.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv http://hdl.handle.net/20.500.12105/6793
url http://hdl.handle.net/20.500.12105/6793
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
Atribución 4.0 Internacional
http://creativecommons.org/licenses/by/4.0/
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
Atribución 4.0 Internacional
http://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Public Library of Science (PLOS)
publisher.none.fl_str_mv Public Library of Science (PLOS)
dc.source.none.fl_str_mv reponame:Repisalud
instname:Instituto de Salud Carlos III (ISCIII)
instname_str Instituto de Salud Carlos III (ISCIII)
reponame_str Repisalud
collection Repisalud
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869409557467365376
score 15,811543

Similares en LA Referencia